NVCR News and Press, NovoCure Limited From 07/15/21

Awards totaling more than $2 million aim to promote and support innovative research on Tumor Treating Fields to deepen understanding and accelerate the development of new treatment strategies Novocure (NASDAQ: NVCR) today announced the recipients of the 3rd Annual AACR-Novoc...

Stocks with the highest sales growth rates have been among the very top performers in recent years, albeit with plenty of volatility included. However, the group is showing weakness in recent trading sessions, and the media’s fear-mongering narratives (about this being the star...

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2021 on Thursday, July 29, 2021, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the thr...

Matteo Colombo/DigitalVision via Getty Images S&P 500 Health Care Sector Index rose ~2.0% over the week to outpace the ~1.7% gain in the S&P 500 as gene editing companies rallied after Intellia (NTLA) and Regeneron (REGN) showed promise in the CRISPR technology with fir...

NovoCure is an attractive, high-growth, oncology company with a large market opportunity. The shares are particularly volatile following yesterday's liver cancer study results, which has created an attractive high-income options trade opportunity. We believe this is an attractive ...

Mario13/E+ via Getty Images Arcturus wins new bullish call at Cantor on experimental COVID-19 shot Arcturus Therapeutics (ARCT) has added ~1.3% in the pre-market after Cantor Fitzgerald initiated its coverage with an overweight recommendation highlighting the company’s effort...

Gainers: Alterity Therapeutics Limited (ATHE) +68%.TRxADE HEALTH (MEDS) +57%.Marin Software (MRIN) +45%.Bridgeline Digital (BLIN) +35%.Birks (BGI) +25%.Pulse Biosciences (PLSE) +25%.SGOCO Group (SGOC) +22%.Grid Dynamics Holdings (GDYN) +19%.scPharmaceuticals (SCPH) +18%.U.S. Silica Holdi...

Shares of Novocure (NASDAQ: NVCR) were sliding 15.1% lower as of 11:05 a.m. EDT on Thursday. The decline came after the company announced final results from its phase 2 study evaluating a combination of its Tumor Treating Fields (TTFields) therapy with sorafenib in treating advanced...

Gainers: Alterity Therapeutics (ATHE) +103%, TRxADE HEALTH (MEDS) +62%, Pulse Biosciences (PLSE) +22%, Spero Therapeutics (SPRO) +12%, Kintara Therapeutics (KTRA) +6%.Losers: Citius Pharmaceuticals (CTXR) -21%, Aligos Therapeutics (A...

Borqs Technologies (BRQS) -17%.Verb Technology (VERB) -15%.CureVac (CVAC) -13% on final data from phase 2b/3 trial on COVID vaccine.1stdibs.Com (DIBS) -12%.Newegg Commerce (NEGG) -11%.Weidai (WEI) -11%.NovoCure (NVCR) -10% after final results from mid-stage TTFields liver ...